ReviewCurrent rheumatology reports2012
Interleukin-17 in inflammatory myopathies.
Review in Current rheumatology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- IL-17-driven transcriptional programs in muscle fibroblasts are not required for pathogenesis in murine anti-histidyl-tRNA synthetase (Jo-1) myositis.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Adenosine A2B receptor activation regulates the balance between T helper 17 cells and regulatory T cells, and inhibits regulatory T cells exhaustion in experimental autoimmune myositis.Journal of cachexia, sarcopenia and muscle · 2024Article
- ASM is a therapeutic target in dermatomyositis by regulating the differentiation of naive CD4 + T cells into Th17 and Treg subsets.Skeletal muscle · 2024Article
- Genetic association between interleukin-17 and susceptibility to rheumatoid arthritis.BMC medical genomics · 2023Article
- Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?Current issues in molecular biology · 2023Review
- A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome.Clinical rheumatology · 2020Article
- Chikungunya virus replication in skeletal muscle cells is required for disease development.The Journal of clinical investigation · 2020Article
- Crosstalk Between Innate and T Cell Adaptive Immunity With(in) the Muscle.Frontiers in physiology · 2020Review
- Reduced miR-146a Promotes REG3A Expression and Macrophage Migration in Polymyositis and Dermatomyositis.Frontiers in immunology · 2020Article
- Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon.Pediatric rheumatology online journal · 2019Review
- Induction of Osmolyte Pathways in Skeletal Muscle Inflammation: Novel Biomarkers for Myositis.Frontiers in neurology · 2018Article
- Blockade of Store-Operated Calcium Entry Reduces IL-17/TNF Cytokine-Induced Inflammatory Response in Human Myoblasts.Frontiers in immunology · 2018Article
- Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.Chinese medical journal · 2017Article
- Dermatomyositis Associated with Sarcoidosis: Two Cases.European journal of case reports in internal medicine · 2017Article
- Doxycycline Inhibits IL-17-Stimulated MMP-9 Expression by Downregulating ERK1/2 Activation: Implications in Myogenic Differentiation.Mediators of inflammation · 2016Article
- Review
- Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review.Clinical reviews in allergy & immunology · 2015Review
- Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies.International journal of molecular sciences · 2015Review
- Interleukin-17 and its implication in the regulation of differentiation and function of hematopoietic and mesenchymal stem cells.Mediators of inflammation · 2015Review
- Selected Aspects in the Pathogenesis of Autoimmune Diseases.Mediators of inflammation · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the identification of interleukin (IL)-17 as a T-cell-derived cytokine 15 years ago, the contribution of the T-helper type 17 (Th17) pathway in inducing and maintaining chronic inflammation has been well-established, particularly in rheumatoid arthritis. In addition to the main Th1 profile first suggested to contribute to inflammatory myopathies, the presence in inflamed muscle tissue of myositis of IL-17-producing cells, in association with activated dendritic cells, suggests a local activation of the IL-23-Th17 pathway. IL-17 can act on muscle cells together with proinflammatory cytokines produced by monocytes and innate immunity to amplify the immune response that could lead to muscle destruction. Evidence for activation of the Th17 pathway in myositis lesions and in vitro effects of IL-17 on muscle cells suggest IL-17 as a therapeutic target. Inhibitors of IL-17 have been tested in other inflammatory conditions, but the position of IL-17 inhibition in the treatment of inflammatory myopathies remains to be defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.